From: Angiogenesis inhibitors in the treatment of prostate cancer
Drug(s) | Â | N | Population | Clinical benefit | Ref |
---|---|---|---|---|---|
VEGF monoclonal antibody | Â | Â | Â | Â | Â |
Bevacizumab 10 mg/kg q2wk × 6 | Ph II | 15 | mCRPC | 4 of 15 had PSA decline < 50% No PSA decline > 50% No objective responses | [30] |
Bevacizumab 15 mg/kg d2 Docetaxel 70 mg/m2 q3wk Estramustine 280 mg TID d1-5 | PhII | 79 | mCRPC | PSA response > 50% in 77% of patients 42% with radiographic partial response | |
Bevacizumab 10 mg/kg q3wk Docetaxel 60 mg/m2 | PhII | 20 | mCRPC, docetaxel failure | PSA response > 50% in 55% of patients 3 of 8 patients had objective radiographic response | [34] |
Tyrosine Kinase Inhibitor | Â | Â | Â | Â | Â |
Sorafenib 400 mg BID | PhII | 22 | mCRPC, | No PSA decline > 50% No objective radiographic responses | [36] |
Sorafenib 400 mg BID | PhII | 28 | CRPC, docetaxel-naïve | PSA response > 50% in 1 patient (3.6%) No objective radiographic responses | [37] |
Sorafenib 400 mg BID | PhII | 55 | CRPC, docetaxel-naïve | PSA response > 50% in 2 patients (3.6%) No objective radiographic responses | [38] |
Sunitinib 50 mg/day × 4 wks of 6 wk cycle | PhII | 34 | CRPC | PSA response > 50% in 2 patients (5.9%) 1 objective radiographic response (2.9%) | [40] |
Thalidomide | Â | Â | Â | Â | Â |
Thalidomide 200 mg/day | PhII | 63 | CRPC | PSA response > 50% in 14% of patients No objective radiographic responses | [43] |
Thalidomide 200 mg/day | PhIII | 159 | bCSPC | Crossover design, time to restarting intermittent ADT Time to PSA progression favored thalidomide group 15 v 9.6 mo, p = 0.21 in first phase 17.1 v 6.6 mo, p = 0002 in second phase | [45] |
Thalidomide 200 mg/day Docetaxel 30 mg/m2 d1, 8, 15 of 28 day cycle | rPhII | 75 | mCRPC, docetaxel-naïve | PSA response > 50% in 53% of thalidomide group vs PSA response > 50% in 37% of control group (p = 0.32) OS of 25.9 mo in thalidomide group vs OS of 14.7 mo in control group (p = 0.0407) | |
Thalidomide 200 mg/day Docetaxel 30 mg/m2 d1, 8, 15 Estramustine TID d1-3, 8-10, 15-17 of 28 day cycle | PhII | 20 | mCRPC, docetaxel-naïve | PSA response > 50% in 90% of patients | [49] |
Thalidomide 200 mg/day Docetaxel 75 mg/m2 q3wk Bevacizumab 15 mg/kg q3wk | PhII | 60 | mCRPC, docetaxel-naïve | PSA response > 50% in 88% of patients | [50] |
Pending Phase III studies | Â | Â | Â | Â | Â |
Docetaxel + Prednisone +/- Bevacizumab | PhIII | 1050 | mCRPC, docetaxel-naïve | Preliminary results indicate no benefit in overall survival for bevacizumab arm | [35] |
Docetaxel + Prednisone +/- Lenalidomide | PhIII | 1015* | mCRPC, docetaxel-naïve | Results pending | NCT00988208 |
Prednisone +/- Sunitinib | PhIII | 819* | mCRPC, docetaxel failure | Results pending | NCT00676650 |